Project Details
Projekt
Comprehensive preclinical pharmacology testing of drugs used for glioblastoma treatment (C01)
Subject Area
Hematology, Oncology
Term
since 2019
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 404521405
In order to prioritize the preclinical development of drugs & biologicals (and combinations thereof) according to their pharmacological characteristics, we will screen potentially effective drug candidates for their brain accessibility and confirm blood-brain-barrier permeation in vivo and over time using microdialysis. Drug candidates with insufficient brain access will be subject to drug-delivery development using cell-penetrating liposomes for packaging, which will be re-evaluated for their brain accessibility. Final efficacy evaluation of promising drugs and drug delivery candidates will be based on the UNITE Core Collection of orthotopic preclinical models of different molecular subgroups of glioblastoma (genetic mouse models with an intact immune system and patient-derived xenograft models transplanted into immunodeficient mice).
DFG Programme
Collaborative Research Centres
Applicant Institution
Ruprecht-Karls-Universität Heidelberg
Project Heads
Dr. Gzona Bajraktari, since 11/2023; Professor Dr. Walter Emil Haefeli, until 6/2023; Professor Dr. Stefan Pfister; Dr. Max Sauter, until 10/2023
